1887

Abstract

Candidate human immunodeficiency virus type 1 (HIV-1) vaccines focusing on T-cell induction, constructed as pTHr.HIVA DNA and modified vaccinia virus Ankara (MVA).HIVA, were delivered in a heterologous prime–boost regimen. The vaccines were tested in several hundred healthy or HIV-1-infected volunteers in Europe and Africa. Whilst larger trials of hundreds of volunteers suggested induction of HIV-1-specific T-cell responses in <15 % of healthy vaccinees, a series of small, rapid trials in 12–24 volunteers at a time with a more in-depth analysis of vaccine-elicited T-cell responses proved to be highly informative and provided more encouraging results. These trials demonstrated that the pTHr.HIVA vaccine alone primed consistently weak and mainly CD4, but also CD8 T-cell responses, and the MVA.HIVA vaccine delivered a consistent boost to both CD4 and CD8 T cells, which was particularly strong in HIV-1-infected patients. Thus, whilst the search is on for ways to enhance T-cell priming, MVA is a useful boosting vector for human subunit genetic vaccines.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82493-0
2007-01-01
2020-01-24
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/1/1.html?itemId=/content/journal/jgv/10.1099/vir.0.82493-0&mimeType=html&fmt=ahah

References

  1. AIDS Vaccine Evaluation Group 022 Protocol Team ( 2001; ). Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. J Infect Dis 183, 563–570.[CrossRef]
    [Google Scholar]
  2. Allen, T. M., Vogel, T. U., Fuller, D. H., Mothe, B. R., Steffen, S., Boyson, J. E., Shipley, T., Fuller, J., Hanke, T. & other authors ( 2000; ). Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J Immunol 164, 4968–4978.[CrossRef]
    [Google Scholar]
  3. Allen, T. M., Jing, P., Calore, B., Horton, H., O'Connor, D. H., Hanke, T., Piekarczyk, M., Ruddersdorf, R., Mothe, B. R. & other authors ( 2002; ). Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol 76, 10507–10511.[CrossRef]
    [Google Scholar]
  4. Amara, R. R., Villinger, F., Altman, J. D., Lydy, S. L., O'Neil, S. P., Staprans, S. I., Montefiori, D. C., Xu, Y., Herndon, J. G. & other authors ( 2001; ). Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science 292, 69–74.[CrossRef]
    [Google Scholar]
  5. Anonymous ( 2002; ). Use of AAV vectors in AIDS vaccine. Expert Rev Vaccines 1, 7.
    [Google Scholar]
  6. Anonymous ( 2004; ). NIAID begins enrolling volunteers for Phase IIB study of Merck's vaccine. IAVI Rep 9, 16.
    [Google Scholar]
  7. Anonymous ( 2005; ). Clinical trials yield promising results from two adenovirus-based vaccines. IAVI Rep 9, 24.
    [Google Scholar]
  8. Appay, V., Dunbar, P. R., Callan, M., Klenerman, P., Gillespie, G. M., Papagno, L., Ogg, G. S., King, A., Lechner, F. & other authors ( 2002; ). Memory CD8+ T cells vary in differentiation phenotype in different persistent virus infections. Nat Med 8, 379–385.[CrossRef]
    [Google Scholar]
  9. Barber, D. L., Wherry, E. J., Masopust, D., Zhu, B., Allison, J. P., Sharpe, A. H., Freeman, G. J. & Ahmed, R. ( 2006; ). Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439, 682–687.[CrossRef]
    [Google Scholar]
  10. Barouch, D. H. & Nabel, G. J. ( 2005; ). Adenovirus vector-based vaccines for human immunodeficiency virus type 1. Hum Gene Ther 16, 149–156.[CrossRef]
    [Google Scholar]
  11. Barouch, D. H., Santra, S., Schmitz, J. E., Kuroda, M. J., Fu, T. M., Wagner, W., Bilska, M., Craiu, A., Zheng, X. X. & other authors ( 2000; ). Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 290, 486–492.[CrossRef]
    [Google Scholar]
  12. Barouch, D. H., Santra, S., Tenner-Racz, K., Racz, P., Kuroda, M. J., Schmitz, J. E., Jackson, S. S., Lifton, M. A., Freed, D. C. & other authors ( 2002; ). Potent CD4+ T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J Immunol 168, 562–568.[CrossRef]
    [Google Scholar]
  13. Belshe, R. B., Gorse, G. J., Mulligan, M. J., Evans, T. G., Keefer, M. C., Excler, J. L., Duliege, A. M., Tartaglia, J., Cox, W. I. & other authors ( 1998; ). Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12, 2407–2415.[CrossRef]
    [Google Scholar]
  14. Bins, A. D., Jorritsma, A., Wolkers, M. C., Hung, C. F., Wu, T. C., Schumacher, T. N. & Haanen, J. B. ( 2005; ). A rapid and potent DNA vaccination strategy defined by in vivo monitoring of antigen expression. Nat Med 11, 899–904.[CrossRef]
    [Google Scholar]
  15. Cao, H., Kaleebu, P., Hom, D., Flores, J., Agrawal, D., Jones, N., Serwanga, J., Okello, M., Walker, C. & other authors ( 2003; ). Immunogenicity of a recombinant human immunodeficiency virus (HIV)-canarypox vaccine in HIV-seronegative Ugandan volunteers: results of the HIV Network for Prevention Trials 007 Vaccine Study. J Infect Dis 187, 887–895.[CrossRef]
    [Google Scholar]
  16. Casimiro, D. R., Bett, A. J., Fu, T. M., Davies, M. E., Tang, A., Wilson, K. A., Chen, M., Long, R., McKelvey, T. & other authors ( 2004; ). Heterologous human immunodeficiency virus type 1 priming-boosting immunization strategies involving replication-defective adenovirus and poxvirus vaccine vectors. J Virol 78, 11434–11438.[CrossRef]
    [Google Scholar]
  17. Cebere, I., Dorrell, L., McShane, H., Simmons, A., McCormack, S., Schmidt, C., Smith, C., Brooks, M., Roberts, J. E. & other authors ( 2006; ). Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers. Vaccine 24, 417–425.[CrossRef]
    [Google Scholar]
  18. Chakrabarti, S., Brechling, K. & Moss, B. ( 1985; ). Vaccinia virus expression vector: coexpression of β-galactosidase provides visual screening of recombinant virus plaques. Mol Cell Biol 5, 3403–3409.
    [Google Scholar]
  19. Choi, M. J. & Maibach, H. I. ( 2003; ). Topical vaccination of DNA antigens: topical delivery of DNA antigens. Skin Pharmacol Appl Skin Physiol 16, 271–282.[CrossRef]
    [Google Scholar]
  20. Cosma, A., Nagaraj, R., Buhler, S., Hinkula, J., Busch, D. H., Sutter, G., Goebel, F. D. & Erfle, V. ( 2003; ). Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22, 21–29.[CrossRef]
    [Google Scholar]
  21. Czerkinsky, C. C., Tarkowski, A., Nilsson, L. A., Ouchterlony, O., Nygren, H. & Gretzer, C. ( 1984; ). Reverse enzyme-linked immunospot assay (RELISPOT) for the detection of cells secreting immunoreactive substances. J Immunol Methods 72, 489–496.[CrossRef]
    [Google Scholar]
  22. Davenport, M. P., Ribeiro, R. M., Chao, D. L. & Perelson, A. S. ( 2004; ). Predicting the impact of a nonsterilizing vaccine against human immunodeficiency virus. J Virol 78, 11340–11351.[CrossRef]
    [Google Scholar]
  23. Davis, N. L., West, A., Reap, E., Macdonald, G., Collier, M., Dryga, S., Maughan, M., Connell, M., Walker, C. & other authors ( 2002; ). Alphavirus replicon particles as candidate HIV vaccines. IUBMB Life 53, 209–211.[CrossRef]
    [Google Scholar]
  24. Dorrell, L., Yang, H., Iversen, A. K., Conlon, C., Suttill, A., Lancaster, M., Dong, T., Cebere, I., Edwards, A. & other authors ( 2005; ). Therapeutic immunization of highly active antiretroviral therapy-treated HIV-1-infected patients: safety and immunogenicity of an HIV-1 gag/poly-epitope DNA vaccine. AIDS 19, 1321–1323.[CrossRef]
    [Google Scholar]
  25. Dorrell, L., Yang, H., Ondondo, B., Dong, T., di Gleria, K., Suttill, A., Conlon, C., Brown, D., Williams, P. & other authors ( 2006; ). Expansion and diversification of virus-specific T cells following immunization of human immunodeficiency virus type 1 (HIV-1)-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 Gag vaccine. J Virol 80, 4705–4716.[CrossRef]
    [Google Scholar]
  26. Douek, D. C., Kwong, P. D. & Nabel, G. J. ( 2006; ). The rational design of an AIDS vaccine. Cell 124, 677–681.[CrossRef]
    [Google Scholar]
  27. Estcourt, M. J., Ramsay, A. J., Brooks, A., Thomson, S. A., Medveckzy, C. J. & Ramshaw, I. A. ( 2002; ). Prime–boost immunization generates a high frequency, high-avidity CD8+ cytotoxic T lymphocyte population. Int Immunol 14, 31–37.[CrossRef]
    [Google Scholar]
  28. Estcourt, M. J., McMichael, A. J. & Hanke, T. ( 2004; ). DNA vaccines against human immunodeficiency virus type 1. Immunol Rev 199, 144–155.[CrossRef]
    [Google Scholar]
  29. Estcourt, M. J., McMichael, A. J. & Hanke, T. ( 2005a; ). Altered primary CD8+ T cell response to a modified virus Ankara (MVA)-vectored vaccine in the absence of CD4+ T cell help. Eur J Immunol 35, 3460–3467.[CrossRef]
    [Google Scholar]
  30. Estcourt, M. J., Letourneau, S., McMichael, A. J. & Hanke, T. ( 2005b; ). Vaccine route, dose and type of delivery vector determine patterns of primary CD8+ T cell responses. Eur J Immunol 35, 2532–2540.[CrossRef]
    [Google Scholar]
  31. Evans, T. G., Keefer, M. C., Weinhold, K. J., Wolff, M., Montefiori, D., Gorse, G. J., Graham, B. S., McElrath, M. J., Clements-Mann, M.-L. & other authors ( 1999; ). A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. J Infect Dis 180, 290–298.[CrossRef]
    [Google Scholar]
  32. Farina, S. F., Gao, G. P., Xiang, Z. Q., Rux, J. J., Burnett, R. M., Alvira, M. R., Marsh, J., Ertl, H. C. & Wilson, J. M. ( 2001; ). Replication-defective vector based on a chimpanzee adenovirus. J Virol 75, 11603–11613.[CrossRef]
    [Google Scholar]
  33. Ferrantelli, F. & Ruprecht, R. M. ( 2002; ). Neutralizing antibodies against HIV – back in the major leagues? Curr Opin Immunol 14, 495–502.[CrossRef]
    [Google Scholar]
  34. Ferrari, G., Humphrey, W., McElrath, M. J., Excler, J. L., Duliege, A. M., Clements, M. L., Corey, L. C., Bolognesi, D. P. & Weinhold, K. J. ( 1997; ). Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. Proc Natl Acad Sci U S A 94, 1396–1401.[CrossRef]
    [Google Scholar]
  35. Franchini, G., Gurunathan, S., Baglyos, L., Plotkin, S. & Tartaglia, J. ( 2004; ). Poxvirus-based vaccine candidates for HIV: two decades of experience with special emphasis on canarypox vectors. Expert Rev Vaccines 3, S75–S88.[CrossRef]
    [Google Scholar]
  36. Gilbert, S. C., Schneider, J., Plebanski, M., Hannan, C. M., Blanchard, T. J., Smith, G. L. & Hill, A. V. S. ( 1999; ). Ty virus-like particles, DNA vaccines and modified vaccinia virus Ankara; comparison and combinations. Biol Chem 380, 299–303.
    [Google Scholar]
  37. Gilbert, S. C., Schneider, J., Hannan, C. M., Hu, J. T., Plebanski, M., Sinden, R. & Hill, A. V. ( 2002; ). Enhanced CD8 T cell immunogenicity and protective efficacy in a mouse malaria model using a recombinant adenoviral vaccine in heterologous prime-boost immunisation regimes. Vaccine 20, 1039–1045.[CrossRef]
    [Google Scholar]
  38. Global HIV/AIDS Vaccine Enterprise ( 2005; ). The Global HIV/AIDS Vaccine Enterprise: scientific strategic plan. PLoS Med 2, e25.[CrossRef]
    [Google Scholar]
  39. Goonetilleke, N., Moore, S., Dally, L., Winstone, N., Mahmoud, N., Cebere, I., Pinheiro, S., Gillespie, G., Brown, D. & other authors ( 2006; ). Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes. J Virol 80, 4717–4728.[CrossRef]
    [Google Scholar]
  40. Gupta, K., Hudgens, M., Corey, L., McElrath, M. J., Weinhold, K., Montefiori, D. C., Gorse, G. J., Frey, S. E., Keefer, M. C. & other authors ( 2002; ). Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 29, 254–261.[CrossRef]
    [Google Scholar]
  41. Gursel, M., Verthelyi, D., Gursel, I., Ishii, K. J. & Klinman, D. M. ( 2002; ). Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide. J Leukoc Biol 71, 813–820.
    [Google Scholar]
  42. Hanke, T. & McMichael, A. J. ( 2000; ). Design and construction of an experimental HIV-1 vaccine for a year-2000 clinical trial in Kenya. Nat Med 6, 951–955.[CrossRef]
    [Google Scholar]
  43. Hanke, T., Schneider, J., Gilbert, S. C., Hill, A. V. S. & McMichael, A. ( 1998a; ). DNA multi-CTL epitope vaccines for HIV and Plasmodium falciparum: immunogenicity in mice. Vaccine 16, 426–435.[CrossRef]
    [Google Scholar]
  44. Hanke, T., Blanchard, T. J., Schneider, J., Hannan, C. M., Becker, M., Gilbert, S. C., Hill, A. V. S., Smith, G. L. & McMichael, A. ( 1998b; ). Enhancement of MHC class I-restricted peptide-specific T cell induction by a DNA prime/MVA boost vaccination regime. Vaccine 16, 439–445.[CrossRef]
    [Google Scholar]
  45. Hanke, T., Samuel, R. V., Blanchard, T. J., Neumann, V. C., Allen, T. M., Boyson, J. E., Sharpe, A. S., Cook, N., Smith, G. L. & other authors ( 1999; ). Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 73, 7524–7532.
    [Google Scholar]
  46. Hanke, T., McMichael, A. J., Samuel, R. V., Powell, L. A. J., McLoughlin, L., Crome, S. J. & Edlin, A. ( 2002; ). Lack of toxicity and persistence in the mouse associated with administration of candidate DNA- and modified vaccinia virus Ankara (MVA)-based HIV vaccines for Kenya. Vaccine 21, 108–114.[CrossRef]
    [Google Scholar]
  47. Hanke, T., Barnfield, C., Wee, E. G.-T., Ågren, L., Samuel, R. V., Larke, N. & Liljeström, P. ( 2003; ). Construction and immunogenicity in a prime–boost regimen of a Semliki Forest virus-vectored experimental HIV clade A vaccine. J Gen Virol 84, 361–368.[CrossRef]
    [Google Scholar]
  48. Hanke, T., McMichael, A. J., Dennis, M. J., Sharpe, S. A., Powell, L. A. J., McLoughlin, L. & Crome, S. J. ( 2005; ). Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 23, 1507–1514.[CrossRef]
    [Google Scholar]
  49. Harari, A., Zimmerli, S. C. & Pantaleo, G. ( 2004a; ). Cytomegalovirus (CMV)-specific cellular immune responses. Hum Immunol 65, 500–506.[CrossRef]
    [Google Scholar]
  50. Harari, A., Vallelian, F. & Pantaleo, G. ( 2004b; ). Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol 34, 3525–3533.[CrossRef]
    [Google Scholar]
  51. Harrer, E., Bauerle, M., Ferstl, B., Chaplin, P., Petzold, B., Mateo, L., Handley, A., Tzatzaris, M., Vollmar, J. & other authors ( 2005; ). Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 nef-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antivir Ther 10, 285–300.
    [Google Scholar]
  52. Haynes, J. R., Fuller, D. H., McCabe, D., Swain, W. F. & Widera, G. ( 1996; ). Induction and characterization of humoral and cellular immune responses elicited via gene gun-mediated nucleic acid immunization. Adv Drug Delivery Rev 21, 3–18.[CrossRef]
    [Google Scholar]
  53. Hutchings, C. L., Gilbert, S. C., Hill, A. V. & Moore, A. C. ( 2005; ). Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175, 599–606.[CrossRef]
    [Google Scholar]
  54. Im, E.-J. & Hanke, T. ( 2004; ). MVA as a vector for vaccines against HIV-1. Expert Rev Vaccines 3, S89–S97.[CrossRef]
    [Google Scholar]
  55. Im, E.-J., Nkolola, J. P., di Gleria, K., McMichael, A. J. & Hanke, T. ( 2006; ). Induction of long-lasting multi-specific CD8+ T cells by a four-component DNA-MVA/HIVA-RENTA candidate HIV-1 vaccine in rhesus macaques. Eur J Immunol 36, 2574–2584.[CrossRef]
    [Google Scholar]
  56. Jin, X., Ramanathan, M., Jr, Barsoum, S., Deschenes, G. R., Ba, L., Binley, J., Schiller, D., Bauer, D. E., Chen, D. C. & other authors ( 2002; ). Safety and immunogenicity of ALVAC vCP1452 and recombinant gp160 in newly human immunodeficiency virus type 1-infected patients treated with prolonged highly active antiretroviral therapy. J Virol 76, 2206–2216.[CrossRef]
    [Google Scholar]
  57. Korber, B., Foley, B., Leitner, T., McCutchan, F., Hahn, B., Mellors, J. W., Myers, G. & Kuiken, C. (editors) ( 1997; ). Human retroviruses and AIDS 1997: a complilation and analysis of nucleic acid and amino acid sequences. Los Alamos, NM: Los Alamos National Laboratory.
  58. Koshkina, N. V., Agoulnik, I. Y., Melton, S. L., Densmore, C. L. & Knight, V. ( 2003; ). Biodistribution and pharmacokinetics of aerosol and intravenously administered DNA-polyethyleneimine complexes: optimization of pulmonary delivery and retention. Mol Ther 8, 249–254.[CrossRef]
    [Google Scholar]
  59. Lalvani, A., Brookes, R., Hambleton, S., Britton, W. J., Hill, A. V. S. & McMichael, A. J. ( 1997; ). Rapid effector function in CD8+ memory T cells. J Exp Med 186, 859–865.[CrossRef]
    [Google Scholar]
  60. Larke, N., Murphy, A., Wirblich, C., Teoh, D., Estcourt, M. J., McMichael, A. J., Roy, P. & Hanke, T. ( 2005; ). Induction of human immunodeficiency virus type 1-specific T cells by a bluetongue virus tubule-vectored vaccine prime-recombinant modified virus Ankara boost regimen. J Virol 79, 14822–14833.[CrossRef]
    [Google Scholar]
  61. Leifer, C. A., Verthelyi, D. & Klinman, D. M. ( 2003; ). Heterogeneity in the human response to immunostimulatory CpG oligodeoxynucleotides. J Immunother 26, 313–319.[CrossRef]
    [Google Scholar]
  62. Levy, Y., Gahery-Segard, H., Durier, C., Lascaux, A. S., Goujard, C., Meiffredy, V., Rouzioux, C., El Habib, R., Beumont-Mauviel, M. & other authors ( 2005; ). Immunological and virological efficacy of a therapeutic immunization combined with interleukin-2 in chronically HIV-1 infected patients. AIDS 19, 279–286.
    [Google Scholar]
  63. Levy, Y., Durier, C., Lascaux, A. S., Meiffredy, V., Gahery-Segard, H., Goujard, C., Rouzioux, C., Resch, M., Guillet, J. G. & other authors ( 2006; ). Sustained control of viremia following therapeutic immunization in chronically HIV-1-infected individuals. AIDS 20, 405–413.[CrossRef]
    [Google Scholar]
  64. Maino, V. C. & Picker, L. J. ( 1998; ). Identification of functional subsets by flow cytometry: intracellular detection of cytokine expression. Cytometry 34, 207–215.[CrossRef]
    [Google Scholar]
  65. McShane, H., Pathan, A. A., Sander, C. R., Keating, S. M., Gilbert, S. C., Huygen, K., Fletcher, H. A. & Hill, A. V. ( 2004; ). Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans. Nat Med 10, 1240–1244.[CrossRef]
    [Google Scholar]
  66. Moorthy, V. S., Pinder, M., Reece, W. H., Watkins, K., Atabani, S., Hannan, C., Bojang, K., McAdam, K. P., Schneider, J. & other authors ( 2003; ). Safety and immunogenicity of DNA/modified vaccinia virus Ankara malaria vaccination in African adults. J Infect Dis 188, 1239–1244.[CrossRef]
    [Google Scholar]
  67. Mosteller, R. D. ( 1987; ). Simplified calculation of body-surface area. N Engl J Med 317, 1098.
    [Google Scholar]
  68. Musey, L., Ding, Y., Elizaga, M., Ha, R., Celum, C. & McElrath, M. J. ( 2003; ). HIV-1 vaccination administered intramuscularly can induce both systemic and mucosal T cell immunity in HIV-1-uninfected individuals. J Immunol 171, 1094–1101.[CrossRef]
    [Google Scholar]
  69. Mwau, M., McMichael, A. J. & Hanke, T. ( 2002; ). Design and validation of an enzyme-linked immunospot assay for use in clinical trials of candidate HIV vaccines. AIDS Res Hum Retroviruses 18, 611–618.[CrossRef]
    [Google Scholar]
  70. Mwau, M., Cebere, I., Sutton, J., Chikoti, P., Winstone, N., Wee, E. G.-T., Beattie, T., Chen, Y.-H., Dorrel, L. & other authors ( 2004; ). A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 85, 911–919.[CrossRef]
    [Google Scholar]
  71. Nkolola, J. P., Wee, E. G.-T., Im, E.-J., Jewell, C. P., Chen, N., Xu, X.-N., McMichael, A. J. & Hanke, T. ( 2004; ). Engineering RENTA, a DNA prime-MVA boost HIV vaccine tailored for Eastern and Central Africa. Gene Ther 11, 1068–1080.[CrossRef]
    [Google Scholar]
  72. Nordström, E. K. L., Forsell, M. N. E., Barnfield, C., Bonin, E., Hanke, T., Sundström, M., Karlsson, G. B. & Liljeström, P. ( 2005; ). Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J Gen Virol 86, 349–354.[CrossRef]
    [Google Scholar]
  73. Ondondo, B. O., Yang, H., Dong, T., di Gleria, K., Suttill, A., Conlon, C., Brown, D., Williams, P., Rowland-Jones, S. L. & other authors ( 2006; ). Immunisation with recombinant modified vaccinia virus Ankara expressing HIV-1 gag in HIV-1-infected subjects stimulates broad functional CD4+ T cell responses. Eur J Immunol 36, 2585–2594.[CrossRef]
    [Google Scholar]
  74. Raviprakash, K., Ewing, D., Simmons, M., Porter, K. R., Jones, T. R., Hayes, C. G., Stout, R. & Murphy, G. S. ( 2003; ). Needle-free Biojector injection of a dengue virus type 1 DNA vaccine with human immunostimulatory sequences and the GM-CSF gene increases immunogenicity and protection from virus challenge in Aotus monkeys. Virology 315, 345–352.[CrossRef]
    [Google Scholar]
  75. Robbins, G. K., Addo, M. M., Troung, H., Rathod, A., Habeeb, K., Davis, B., Heller, H., Basgoz, N., Walker, B. D. & Rosenberg, E. S. ( 2003; ). Augmentation of HIV-1-specific T helper cell responses in chronic HIV-1 infection by therapeutic immunization. AIDS 17, 1121–1126.[CrossRef]
    [Google Scholar]
  76. Roberts, D. M., Nanda, A., Havenga, M. J., Abbink, P., Lynch, D. M., Ewald, B. A., Liu, J., Thorner, A. R., Swanson, P. E. & other authors ( 2006; ). Hexon-chimaeric adenovirus serotype 5 vectors circumvent pre-existing anti-vector immunity. Nature 441, 239–243.[CrossRef]
    [Google Scholar]
  77. Rosenberg, E. S., Billingsley, J. M., Caliendo, A. M., Boswell, S. L., Sax, P. E., Kalams, S. A. & Walker, B. D. ( 1997; ). Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia. Science 278, 1447–1450.[CrossRef]
    [Google Scholar]
  78. Rowland-Jones, S. L., Pinheiro, S., Kaul, R., Hansasuta, P., Gillespie, G., Dong, T., Plummer, F. A., Bwayo, J. B., Fidler, S. & other authors ( 2001; ). How important is the ‘quality’ of the cytotoxic T lymphocyte (CTL) response in protection against HIV infection? Immunol Lett 79, 15–20.[CrossRef]
    [Google Scholar]
  79. Santra, S., Barouch, D. H., Korioth-Schmitz, B., Lord, C. I., Krivulka, G. R., Yu, F., Beddall, M. H., Gorgone, D. A., Lifton, M. A. & other authors ( 2004; ). Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. Proc Natl Acad Sci U S A 101, 11088–11093.[CrossRef]
    [Google Scholar]
  80. Schneider, J., Gilbert, S. C., Blanchard, T. J., Hanke, T., Robson, K. J., Hannan, C. M., Becker, M., Sinden, R., Smith, G. L. & Hill, A. V. S. ( 1998; ). Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat Med 4, 397–402.[CrossRef]
    [Google Scholar]
  81. Schulz, O., Diebold, S. S., Chen, M., Naslund, T. I., Nolte, M. A., Alexopoulou, L., Azuma, Y. T., Flavell, R. A., Liljeström, P. & other authors ( 2005; ). Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433, 887–892.[CrossRef]
    [Google Scholar]
  82. Slyker, J. A., Lohman, B. L., Mbori-Ngacha, D. A., Reilly, M., Wee, E. G., Dong, T., McMichael, A. J., Rowland-Jones, S. L., Hanke, T. & John-Stewart, G. ( 2005; ). Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. Vaccine 23, 4711–4719.[CrossRef]
    [Google Scholar]
  83. Sun, J. C., Williams, M. A. & Bevan, M. J. ( 2004; ). CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5, 927–933.[CrossRef]
    [Google Scholar]
  84. Tubiana, R., Carcelain, G., Vray, M., Gourlain, K., Dalban, C., Chermak, A., Rabian, C., Vittecoq, D., Simon, A. & other authors ( 2005; ). Therapeutic immunization with a human immunodeficiency virus (HIV) type 1-recombinant canarypox vaccine in chronically HIV-infected patients: The Vacciter Study (ANRS 094). Vaccine 23, 4292–4301.[CrossRef]
    [Google Scholar]
  85. UNAIDS ( 2004; ). AIDS Epidemic Update: December 2004. Geneva: UNAIDS/WHO. http://www.who.int/hiv/pub/epidemiology/epiupdate/en/index.html
  86. van Baalen, C. A., Guillon, C., van Baalen, M., Verschuren, E. J., Boers, P. H., Osterhaus, A. D. & Gruters, R. A. ( 2002; ). Impact of antigen expression kinetics on the effectiveness of HIV-specific cytotoxic T lymphocytes. Eur J Immunol 32, 2644–2652.[CrossRef]
    [Google Scholar]
  87. Vordermeier, H. M., Rhodes, S. G., Dean, G., Goonetilleke, N., Huygen, K., Hill, A. V., Hewinson, R. G. & Gilbert, S. C. ( 2004; ). Cellular immune responses induced in cattle by heterologous prime-boost vaccination using recombinant viruses and bacille Calmette-Guerin. Immunology 112, 461–470.[CrossRef]
    [Google Scholar]
  88. Vuola, J. M., Keating, S., Webster, D. P., Berthoud, T., Dunachie, S., Gilbert, S. C. & Hill, A. V. ( 2005; ). Differential immunogenicity of various heterologous prime-boost vaccine regimens using DNA and viral vectors in healthy volunteers. J Immunol 174, 449–455.[CrossRef]
    [Google Scholar]
  89. Webster, D. P., Dunachie, S., Vuola, J. M., Berthoud, T., Keating, S., Laidlaw, S. M., McConkey, S. J., Poulton, I., Andrews, L. & other authors ( 2005; ). Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara. Proc Natl Acad Sci U S A 102, 4836–4841.[CrossRef]
    [Google Scholar]
  90. Wee, E. G.-T., Patel, S., McMichael, A. J. & Hanke, T. ( 2002; ). A DNA/MVA-based candidate human immunodeficiency virus vaccine for Kenya induces multi-specific T cell responses in rhesus macaques. J Gen Virol 83, 75–80.
    [Google Scholar]
  91. Williams, S. G., Cranenburgh, R. M., Weiss, A. M. E., Wrighton, C. J., Sherratt, D. J. & Hanak, J. A. J. ( 1998; ). Repressor titration: a novel system for selection and stable maintenance of recombinant plasmids. Nucleic Acids Res 26, 2120–2124.[CrossRef]
    [Google Scholar]
  92. Williams, A., Goonetilleke, N. P., McShane, H., Clark, S. O., Hatch, G., Gilbert, S. C. & Hill, A. V. ( 2005; ). Boosting with poxviruses enhances Mycobacterium bovis BCG efficacy against tuberculosis in guinea pigs. Infect Immun 73, 3814–3816.[CrossRef]
    [Google Scholar]
  93. Zhang, D., Shankar, P., Xu, Z., Harnisch, B., Chen, G., Lange, C., Lee, S. J., Valdez, H., Lederman, M. M. & Lieberman, J. ( 2003a; ). Most antiviral CD8 T cells during chronic viral infection do not express high levels of perforin and are not directly cytotoxic. Blood 101, 226–235.[CrossRef]
    [Google Scholar]
  94. Zhang, L., Widera, G., Bleecher, S., Zaharoff, D. A., Mossop, B. & Rabussay, D. ( 2003b; ). Accelerated immune response to DNA vaccines. DNA Cell Biol 22, 815–822.[CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82493-0
Loading
/content/journal/jgv/10.1099/vir.0.82493-0
Loading

Data & Media loading...

Most cited articles

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error